Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

870 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.
Filippi AR, Piva C, Levis M, Chiappella A, Caracciolo D, Bellò M, Bisi G, Vitolo U, Ricardi U. Filippi AR, et al. Among authors: bello m. Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1239-43. doi: 10.1016/j.ijrobp.2016.02.057. Epub 2016 Mar 2. Int J Radiat Oncol Biol Phys. 2016. PMID: 27130796
Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona R, Vitolo U, Bisi G, Ricardi U. Filippi AR, et al. Among authors: bello m. Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):311-6. doi: 10.1016/j.ijrobp.2013.05.053. Epub 2013 Aug 2. Int J Radiat Oncol Biol Phys. 2013. PMID: 23916170 Free article.
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C, Botto B, Passera R, Bellò M, Benevolo G, Boccomini C, Castellino A, Chiappella A, Freilone R, Nicolosi M, Orsucci L, Pecoraro C, Pregno P, Bisi G, Vitolo U. Ciochetto C, et al. Among authors: bello m. Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16. Ann Hematol. 2018. PMID: 29663029 Clinical Trial.
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy.
Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P. Deandreis D, et al. Among authors: bello m. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2804-2815. doi: 10.1007/s00259-020-04809-8. Epub 2020 Apr 20. Eur J Nucl Med Mol Imaging. 2020. PMID: 32314028
Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.
Ceci F, Rovera G, Iorio GC, Guarneri A, Chiofalo V, Passera R, Oderda M, Dall'Armellina S, Liberini V, Grimaldi S, Bellò M, Gontero P, Ricardi U, Deandreis D. Ceci F, et al. Among authors: bello m. Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3257-3268. doi: 10.1007/s00259-022-05741-9. Epub 2022 Feb 26. Eur J Nucl Med Mol Imaging. 2022. PMID: 35217883 Free PMC article.
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U. Pregno P, et al. Among authors: bello m. Blood. 2012 Mar 1;119(9):2066-73. doi: 10.1182/blood-2011-06-359943. Epub 2012 Jan 10. Blood. 2012. PMID: 22234681 Free article.
870 results